Literature DB >> 27358857

MicroRNAs as biomarkers in leukemia.

Xinxin Wang1, Baohua Zhu1, Zunnan Huang1, Liyong Chen1, Zhiwei He1, Hua Zhang1.   

Abstract

Current diagnostic and prognostic markers still exhibit biological limitation and seeking novel molecular biomarkers is crucial for early clinical diagnosis and in the development of novel strategies for leukemia therapy. Emerging evidence showed that dysregulated microRNAs (miRNAs) play important roles in cancer including leukemia. In this review, we summarized recent progress on the role of miRNAs in leukemia, mainly focusing on recent findings that suggest the potential of miRNAs as biomarkers for diagnosis and prognosis. Notably, the circulating miRNAs were also discussed for the fact that they can be detected in body fluids, and thus represent a novel source of promising biomarkers that may be applied to clinical settings.

Entities:  

Keywords:  MicroRNA (miRNAs); biomarker; leukemia

Year:  2014        PMID: 27358857      PMCID: PMC4923504          DOI: 10.3978/j.issn.2306-9759.2014.04.01

Source DB:  PubMed          Journal:  Stem Cell Investig        ISSN: 2306-9759


  54 in total

1.  MicroRNA-223 expression is uniformly down-regulated in B cell lymphoproliferative disorders and is associated with poor survival in patients with chronic lymphocytic leukemia.

Authors:  Keshu Zhou; Shuhua Yi; Zhen Yu; Zengjun Li; Yanying Wang; Dehui Zou; Junyuan Qi; Yaozhong Zhao; Lugui Qiu
Journal:  Leuk Lymphoma       Date:  2012-01-31

2.  MIR29B regulates expression of MLLT11 (AF1Q), an MLL fusion partner, and low MIR29B expression associates with adverse cytogenetics and poor overall survival in AML.

Authors:  Yin Xiong; Zejuan Li; Min Ji; Aik-Choon Tan; Judson Bemis; Jove-Victor Tse; Gang Huang; Jino Park; Chunyan Ji; Jianjun Chen; Lynne T Bemis; Kevin D Bunting; William Tse
Journal:  Br J Haematol       Date:  2011-04-18       Impact factor: 6.998

3.  Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia.

Authors:  Alessandra Ferrajoli; Tait D Shanafelt; Cristina Ivan; Masayoshi Shimizu; Kari G Rabe; Nazila Nouraee; Mariko Ikuo; Asish K Ghosh; Susan Lerner; Laura Z Rassenti; Lianchun Xiao; Jianhua Hu; James M Reuben; Steliana Calin; M James You; John T Manning; William G Wierda; Zeev Estrov; Susan O'Brien; Thomas J Kipps; Michael J Keating; Neil E Kay; George A Calin
Journal:  Blood       Date:  2013-07-02       Impact factor: 22.113

4.  Micro-RNA-16 expression in paraffin-embedded specimen correlates with overall survival of T-lymphoblastic lymphoma/leukemia.

Authors:  Yanfeng Xi; Jing Li; Likun Zan; Jinfen Wang; Guoping Wang; Yi Ning
Journal:  Hum Pathol       Date:  2012-12-20       Impact factor: 3.466

5.  Overexpression of miR-378 is frequent and may affect treatment outcomes in patients with acute myeloid leukemia.

Authors:  Jun Qian; Jiang Lin; Wei Qian; Ji-chun Ma; Si-xuan Qian; Yun Li; Jing Yang; Jian-yong Li; Cui-zhu Wang; Hai-yan Chai; Xing-xing Chen; Zhao-qun Deng
Journal:  Leuk Res       Date:  2013-04-11       Impact factor: 3.156

6.  MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia.

Authors:  Ramiro Garzon; Stefano Volinia; Chang-Gong Liu; Cecilia Fernandez-Cymering; Tiziana Palumbo; Flavia Pichiorri; Muller Fabbri; Kevin Coombes; Hansjuerg Alder; Tatsuya Nakamura; Neal Flomenberg; Guido Marcucci; George A Calin; Steven M Kornblau; Hagop Kantarjian; Clara D Bloomfield; Michael Andreeff; Carlo M Croce
Journal:  Blood       Date:  2008-01-10       Impact factor: 22.113

7.  MicroRNA miR-181a correlates with morphological sub-class of acute myeloid leukaemia and the expression of its target genes in global genome-wide analysis.

Authors:  S Debernardi; S Skoulakis; G Molloy; T Chaplin; A Dixon-McIver; B D Young
Journal:  Leukemia       Date:  2007-03-01       Impact factor: 11.528

8.  Impact on cell to plasma ratio of miR-92a in patients with acute leukemia: in vivo assessment of cell to plasma ratio of miR-92a.

Authors:  Junko H Ohyashiki; Tomohiro Umezu; Chiaki Kobayashi; Ryoko S Hamamura; Masami Tanaka; Masahiko Kuroda; Kazuma Ohyashiki
Journal:  BMC Res Notes       Date:  2010-12-24

Review 9.  The emerging role of MIR-146A in the control of hematopoiesis, immune function and cancer.

Authors:  Catherine Labbaye; Ugo Testa
Journal:  J Hematol Oncol       Date:  2012-03-27       Impact factor: 17.388

10.  Increased expression of miR-221 is associated with shorter overall survival in T-cell acute lymphoid leukemia.

Authors:  Hamilton L Gimenes-Teixeira; Antonio R Lucena-Araujo; Guilherme A Dos Santos; Dalila L Zanette; Priscila S Scheucher; Luciana C Oliveira; Leandro F Dalmazzo; Wilson A Silva-Júnior; Roberto P Falcão; Eduardo M Rego
Journal:  Exp Hematol Oncol       Date:  2013-04-08
View more
  4 in total

1.  Genome-wide identification of microRNA signatures associated with stem/progenitor cells in Philadelphia chromosome-positive acute lymphoblastic leukemia.

Authors:  Ehsan Valiollahi; Josep Maria Ribera; Eulàlia Genescà; Javad Behravan
Journal:  Mol Biol Rep       Date:  2019-02-02       Impact factor: 2.316

Review 2.  Dysregulation of miRNA in Leukemia: Exploiting miRNA Expression Profiles as Biomarkers.

Authors:  Luisa Anelli; Antonella Zagaria; Giorgina Specchia; Pellegrino Musto; Francesco Albano
Journal:  Int J Mol Sci       Date:  2021-07-02       Impact factor: 5.923

3.  Expression Pattern of Long Non-coding RNA Growth Arrest-specific 5 in the Remission Induction Therapy in Childhood Acute Lymphoblastic Leukemia.

Authors:  Vladimir Gasic; Biljana Stankovic; Branka Zukic; Dragana Janic; Lidija Dokmanovic; Nada Krstovski; Jelena Lazic; Goran Milosevic; Marianna Lucafò; Gabriele Stocco; Giuliana Decorti; Sonja Pavlovic; Nikola Kotur
Journal:  J Med Biochem       Date:  2019-05-11       Impact factor: 3.402

Review 4.  Recent Progress on Circular RNA Research in Acute Myeloid Leukemia.

Authors:  Muhammad Jamal; Tianbao Song; Bei Chen; Muhammad Faisal; Zixi Hong; Tian Xie; Yingjie Wu; Shan Pan; Qian Yin; Liang Shao; Qiuping Zhang
Journal:  Front Oncol       Date:  2019-11-06       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.